沐舒坦预防早产儿肺透明膜病  

Use of Ambroxol in prevention of pulmonary hyaline membrane disease of premature infants

作　　者：万俊[1] 凌厉[1] 徐进生[1] 刘静[1] 

机构地区：[1]江阴市人民医院儿科,214400

出　　处：《江苏医药》2003年第8期567-568,共2页Jiangsu Medical Journal

摘　　要：目的 探讨沐舒坦预防早产儿肺透明膜病(HMD)的效果。方法将产前常规应用肾上腺皮质激素预防早产儿肺透明膜病,且产后立即转入新生儿病房的早产儿,共98例随机分成两组。激素+沐舒坦组(治疗组)和单用激素组(对照组),每组49例。治疗组加用沐舒坦20～30mg·kg-1·d-1,连用3～5天观察两组HMD的发生率、窒息儿HMD发生率及不同胎龄儿HMD的发生率。结果 治疗组HMD的发生率为2.1％,对照组HMD的发生率为10.2％,两组有显著性差异(P<0.05)。不同胎龄28～30周,31～32周、33～34周、35～36周HMD发生率:治疗组分别为16.7％、0％、0％、0％,对照组分别为40％、20％、12.5％、0％。窒息儿HMD发生率治疗组为9.1％,对照组为46.2％。结论 早产儿产后立即给予沐舒坦对预防早产儿肺透明膜病有较好疗效。Objective To evaluate the effect of Ambroxol in preventing premature hyaline membrane disease (HMD) in combination with the routine use of corticosteroids. Methods 98 neo-nates,who received corticosteroids in prenatal period and were immediately put in the wards for newborn after delivery,were randomly divided into two groups:treatment group (Ambroxol plus corticosteroids, n=49), and control group (corticosteroids alone, n = 49). Ambroxol for the treatment group was given at 20~30mg · kg-1 · d-1 for 3~5 days. The incidence of HMD for premature infants and those with asphyxia were observed. The incidence of HMD in different fetal ages was also studied. Results HMD incidence of treatment group is 2. 1%,but that of control group is 14. 3%,so the dif-fence is significant (P<0. 05). The incidences in different fetal age brackets are 16. 7% ,0% ,0%,and 0% for 28-30,31 - 32,33~34,and 35~36 weeks,respectively in the treatment group,while those in the control group are 40%,20%, 12. 5% and 0% , respectively. And, the HMD incidence of neonatal asphyxia in treatment group is 9. 1% ,but that in control group is 46. 2%. Conclusion Ambroxol has noticeable effect in the prevention of premature infant HMD in combination with prenatal use of corticosteroids.

关 键 词：沐舒坦 预防 早产儿 肺透明膜病 

分 类 号：R722.6[医药卫生—儿科]